ID   MPI_HUMAN               Reviewed;         423 AA.
AC   P34949; A8K8K9; Q96AB0;
DT   01-FEB-1994, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 2.
DT   24-JAN-2024, entry version 221.
DE   RecName: Full=Mannose-6-phosphate isomerase;
DE            EC=5.3.1.8 {ECO:0000269|PubMed:8307007, ECO:0000305|PubMed:9525984, ECO:0000305|PubMed:9585601};
DE   AltName: Full=Phosphohexomutase;
DE   AltName: Full=Phosphomannose isomerase {ECO:0000303|PubMed:8307007};
DE            Short=PMI {ECO:0000303|PubMed:8307007};
GN   Name=MPI {ECO:0000312|HGNC:HGNC:7216}; Synonyms=PMI1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PARTIAL PROTEIN SEQUENCE, FUNCTION,
RP   CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND SUBCELLULAR
RP   LOCATION.
RC   TISSUE=Placenta, and Testis;
RX   PubMed=8307007; DOI=10.1111/j.1432-1033.1994.tb19954.x;
RA   Proudfoot A.E.I., Turcatti G., Wells T.N.C., Payton M.A., Smith D.J.;
RT   "Purification, cDNA cloning and heterologous expression of human
RT   phosphomannose isomerase.";
RL   Eur. J. Biochem. 219:415-423(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS CDG1B THR-51; ASN-131;
RP   GLN-152; SER-250 AND HIS-418.
RX   PubMed=10980531;
RX   DOI=10.1002/1098-1004(200009)16:3<247::aid-humu7>3.0.co;2-a;
RA   Schollen E., Dorland L., de Koning T.J., Van Diggelen O.P.,
RA   Huijmans J.G.M., Marquardt T., Babovic-Vuksanovic D., Patterson M.,
RA   Imtiaz F., Winchester B., Adamowicz M., Pronicka E., Freeze H.,
RA   Matthijs G.;
RT   "Genomic organization of the human phosphomannose isomerase (MPI) gene and
RT   mutation analysis in patients with congenital disorders of glycosylation
RT   type Ib (CDG-Ib).";
RL   Hum. Mutat. 16:247-252(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Blood, and Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-102 AND SER-108, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [9]
RP   VARIANTS CDG1B LEU-102 AND THR-138, FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=9585601; DOI=10.1086/301873;
RA   Jaeken J., Matthijs G., Saudubray J.-M., Dionisi-Vici C., Bertini E.,
RA   de Lonlay P., Henri H., Carchon H., Schollen E., Van Schaftingen E.;
RT   "Phosphomannose isomerase deficiency: a carbohydrate-deficient glycoprotein
RT   syndrome with hepatic-intestinal presentation.";
RL   Am. J. Hum. Genet. 62:1535-1539(1998).
RN   [10]
RP   VARIANT CDG1B GLN-219, FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=9525984; DOI=10.1172/jci2350;
RA   Niehues R., Hasilik M., Alton G., Koerner C., Schiebe-Sukumar M.,
RA   Koch H.G., Zimmer K.-P., Wu R., Harms E., Reiter K., von Figura K.,
RA   Freeze H.H., Harms H.K., Marquardt T.;
RT   "Carbohydrate-deficient glycoprotein syndrome type Ib: phosphomannose
RT   isomerase deficiency and mannose therapy.";
RL   J. Clin. Invest. 101:1414-1420(1998).
RN   [11]
RP   VARIANTS CDG1B CYS-255 AND THR-398.
RX   PubMed=11134235; DOI=10.1136/jmg.38.1.14;
RA   de Lonlay P., Seta N., Barrot S., Chabrol B., Drouin V., Gabriel B.M.,
RA   Journel H., Kretz M., Laurent J., Le Merrer M., Leroy A., Pedespan D.,
RA   Sarda P., Villeneuve N., Schmitz J., van Schaftingen E., Matthijs G.,
RA   Jaeken J., Koerner C., Munnich A., Saudubray J.-M., Cormier-Daire V.;
RT   "A broad spectrum of clinical presentations in congenital disorders of
RT   glycosylation I: a series of 26 cases.";
RL   J. Med. Genet. 38:14-19(2001).
RN   [12]
RP   VARIANTS CDG1B THR-140 AND GLN-219.
RX   PubMed=11350186; DOI=10.1006/mgme.2001.3161;
RA   Westphal V., Kjaergaard S., Davis J.A., Peterson S.M., Skovby F.,
RA   Freeze H.H.;
RT   "Genetic and metabolic analysis of the first adult with congenital disorder
RT   of glycosylation type Ib: long-term outcome and effects of mannose
RT   supplementation.";
RL   Mol. Genet. Metab. 73:77-85(2001).
RN   [13]
RP   VARIANT CDG1B CYS-129.
RX   PubMed=12357336; DOI=10.1038/sj.ejhg.5200858;
RA   Schollen E., Martens K., Geuzens E., Matthijs G.;
RT   "DHPLC analysis as a platform for molecular diagnosis of congenital
RT   disorders of glycosylation (CDG).";
RL   Eur. J. Hum. Genet. 10:643-648(2002).
RN   [14]
RP   VARIANT CDG1B HIS-295.
RX   PubMed=12414827; DOI=10.1136/jmg.39.11.849;
RA   Vuillaumier-Barrot S., Le Bizec C., de Lonlay P., Barnier A., Mitchell G.,
RA   Pelletier V., Prevost C., Saudubray J.-M., Durand G., Seta N.;
RT   "Protein losing enteropathy-hepatic fibrosis syndrome in Saguenay-Lac St-
RT   Jean, Quebec is a congenital disorder of glycosylation type Ib.";
RL   J. Med. Genet. 39:849-851(2002).
CC   -!- FUNCTION: Isomerase that catalyzes the interconversion of fructose-6-P
CC       and mannose-6-P and has a critical role in the supply of D-mannose
CC       derivatives required for many eukaryotic glycosylation reactions.
CC       {ECO:0000269|PubMed:8307007, ECO:0000305|PubMed:9525984,
CC       ECO:0000305|PubMed:9585601}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=D-mannose 6-phosphate = D-fructose 6-phosphate;
CC         Xref=Rhea:RHEA:12356, ChEBI:CHEBI:58735, ChEBI:CHEBI:61527;
CC         EC=5.3.1.8; Evidence={ECO:0000269|PubMed:8307007,
CC         ECO:0000305|PubMed:9525984, ECO:0000305|PubMed:9585601};
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000250|UniProtKB:P34948};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000250|UniProtKB:P34948};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.23 mM for D-mannose 6-phosphate {ECO:0000269|PubMed:8307007};
CC   -!- PATHWAY: Nucleotide-sugar biosynthesis; GDP-alpha-D-mannose
CC       biosynthesis; alpha-D-mannose 1-phosphate from D-fructose 6-phosphate:
CC       step 1/2.
CC   -!- INTERACTION:
CC       P34949-2; P55212: CASP6; NbExp=3; IntAct=EBI-21823432, EBI-718729;
CC       P34949-2; O00291: HIP1; NbExp=3; IntAct=EBI-21823432, EBI-473886;
CC       P34949-2; P13473-2: LAMP2; NbExp=3; IntAct=EBI-21823432, EBI-21591415;
CC       P34949-2; O75400-2: PRPF40A; NbExp=3; IntAct=EBI-21823432, EBI-5280197;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:Q924M7}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P34949-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P34949-2; Sequence=VSP_013357;
CC   -!- TISSUE SPECIFICITY: Expressed in all tissues, but more abundant in
CC       heart, brain and skeletal muscle. {ECO:0000269|PubMed:8307007}.
CC   -!- DISEASE: Congenital disorder of glycosylation 1B (CDG1B) [MIM:602579]:
CC       A form of congenital disorder of glycosylation, a multisystem disorder
CC       caused by a defect in glycoprotein biosynthesis and characterized by
CC       under-glycosylated serum glycoproteins. Congenital disorders of
CC       glycosylation result in a wide variety of clinical features, such as
CC       defects in the nervous system development, psychomotor retardation,
CC       dysmorphic features, hypotonia, coagulation disorders, and
CC       immunodeficiency. The broad spectrum of features reflects the critical
CC       role of N-glycoproteins during embryonic development, differentiation,
CC       and maintenance of cell functions. CDG1B is clinically characterized by
CC       protein-losing enteropathy. {ECO:0000269|PubMed:10980531,
CC       ECO:0000269|PubMed:11134235, ECO:0000269|PubMed:11350186,
CC       ECO:0000269|PubMed:12357336, ECO:0000269|PubMed:12414827,
CC       ECO:0000269|PubMed:9525984, ECO:0000269|PubMed:9585601}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the mannose-6-phosphate isomerase type 1 family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X76057; CAA53657.1; -; mRNA.
DR   EMBL; AF227218; AAF37697.1; -; Genomic_DNA.
DR   EMBL; AF227216; AAF37697.1; JOINED; Genomic_DNA.
DR   EMBL; AF227217; AAF37697.1; JOINED; Genomic_DNA.
DR   EMBL; AK292374; BAF85063.1; -; mRNA.
DR   EMBL; CH471136; EAW99296.1; -; Genomic_DNA.
DR   EMBL; BC017351; AAH17351.1; -; mRNA.
DR   EMBL; BC046357; AAH46357.1; -; mRNA.
DR   CCDS; CCDS10272.1; -. [P34949-1]
DR   CCDS; CCDS73757.1; -. [P34949-2]
DR   PIR; S41122; S41122.
DR   RefSeq; NP_001276085.1; NM_001289156.1.
DR   RefSeq; NP_001276086.1; NM_001289157.1. [P34949-2]
DR   RefSeq; NP_002426.1; NM_002435.2. [P34949-1]
DR   AlphaFoldDB; P34949; -.
DR   SMR; P34949; -.
DR   BioGRID; 110491; 48.
DR   IntAct; P34949; 11.
DR   MINT; P34949; -.
DR   STRING; 9606.ENSP00000318318; -.
DR   BindingDB; P34949; -.
DR   ChEMBL; CHEMBL2758; -.
DR   DrugCentral; P34949; -.
DR   GlyGen; P34949; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; P34949; -.
DR   MetOSite; P34949; -.
DR   PhosphoSitePlus; P34949; -.
DR   SwissPalm; P34949; -.
DR   BioMuta; MPI; -.
DR   DMDM; 462567; -.
DR   OGP; P34949; -.
DR   EPD; P34949; -.
DR   jPOST; P34949; -.
DR   MassIVE; P34949; -.
DR   MaxQB; P34949; -.
DR   PaxDb; 9606-ENSP00000318318; -.
DR   PeptideAtlas; P34949; -.
DR   ProteomicsDB; 54959; -. [P34949-1]
DR   ProteomicsDB; 54960; -. [P34949-2]
DR   Pumba; P34949; -.
DR   Antibodypedia; 2008; 449 antibodies from 32 providers.
DR   DNASU; 4351; -.
DR   Ensembl; ENST00000323744.10; ENSP00000318192.6; ENSG00000178802.18. [P34949-2]
DR   Ensembl; ENST00000352410.9; ENSP00000318318.6; ENSG00000178802.18. [P34949-1]
DR   GeneID; 4351; -.
DR   KEGG; hsa:4351; -.
DR   MANE-Select; ENST00000352410.9; ENSP00000318318.6; NM_002435.3; NP_002426.1.
DR   UCSC; uc002azc.3; human. [P34949-1]
DR   AGR; HGNC:7216; -.
DR   CTD; 4351; -.
DR   DisGeNET; 4351; -.
DR   GeneCards; MPI; -.
DR   GeneReviews; MPI; -.
DR   HGNC; HGNC:7216; MPI.
DR   HPA; ENSG00000178802; Low tissue specificity.
DR   MalaCards; MPI; -.
DR   MIM; 154550; gene.
DR   MIM; 602579; phenotype.
DR   neXtProt; NX_P34949; -.
DR   OpenTargets; ENSG00000178802; -.
DR   Orphanet; 79319; MPI-CDG.
DR   PharmGKB; PA30922; -.
DR   VEuPathDB; HostDB:ENSG00000178802; -.
DR   eggNOG; KOG2757; Eukaryota.
DR   GeneTree; ENSGT00390000016075; -.
DR   HOGENOM; CLU_026967_2_0_1; -.
DR   InParanoid; P34949; -.
DR   OMA; DIGLFCG; -.
DR   OrthoDB; 1116301at2759; -.
DR   PhylomeDB; P34949; -.
DR   TreeFam; TF312831; -.
DR   PathwayCommons; P34949; -.
DR   Reactome; R-HSA-4043916; Defective MPI causes MPI-CDG.
DR   Reactome; R-HSA-446205; Synthesis of GDP-mannose.
DR   SignaLink; P34949; -.
DR   UniPathway; UPA00126; UER00423.
DR   BioGRID-ORCS; 4351; 69 hits in 1164 CRISPR screens.
DR   GenomeRNAi; 4351; -.
DR   Pharos; P34949; Tchem.
DR   PRO; PR:P34949; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   RNAct; P34949; Protein.
DR   Bgee; ENSG00000178802; Expressed in apex of heart and 170 other cell types or tissues.
DR   ExpressionAtlas; P34949; baseline and differential.
DR   Genevisible; P34949; HS.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0004476; F:mannose-6-phosphate isomerase activity; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0009298; P:GDP-mannose biosynthetic process; IBA:GO_Central.
DR   GO; GO:0061611; P:mannose to fructose-6-phosphate metabolic process; IDA:UniProtKB.
DR   CDD; cd07011; cupin_PMI_type_I_N; 1.
DR   Gene3D; 2.60.120.10; Jelly Rolls; 2.
DR   Gene3D; 1.10.441.10; Phosphomannose Isomerase, domain 2; 1.
DR   InterPro; IPR001250; Man6P_Isoase-1.
DR   InterPro; IPR016305; Mannose-6-P_Isomerase.
DR   InterPro; IPR018050; Pmannose_isomerase-type1_CS.
DR   InterPro; IPR046456; PMI_typeI_C.
DR   InterPro; IPR046457; PMI_typeI_cat.
DR   InterPro; IPR046458; PMI_typeI_hel.
DR   InterPro; IPR014710; RmlC-like_jellyroll.
DR   InterPro; IPR011051; RmlC_Cupin_sf.
DR   NCBIfam; TIGR00218; manA; 1.
DR   PANTHER; PTHR10309; MANNOSE-6-PHOSPHATE ISOMERASE; 1.
DR   PANTHER; PTHR10309:SF0; MANNOSE-6-PHOSPHATE ISOMERASE; 1.
DR   Pfam; PF01238; PMI_typeI_C; 1.
DR   Pfam; PF20511; PMI_typeI_cat; 1.
DR   Pfam; PF20512; PMI_typeI_hel; 1.
DR   PIRSF; PIRSF001480; Mannose-6-phosphate_isomerase; 1.
DR   PRINTS; PR00714; MAN6PISMRASE.
DR   SUPFAM; SSF51182; RmlC-like cupins; 1.
DR   PROSITE; PS00965; PMI_I_1; 1.
DR   PROSITE; PS00966; PMI_I_2; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative splicing; Congenital disorder of glycosylation;
KW   Cytoplasm; Direct protein sequencing; Disease variant; Isomerase;
KW   Metal-binding; Phosphoprotein; Reference proteome; Zinc.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0007744|PubMed:19413330"
FT   CHAIN           2..423
FT                   /note="Mannose-6-phosphate isomerase"
FT                   /id="PRO_0000194235"
FT   ACT_SITE        295
FT                   /evidence="ECO:0000250|UniProtKB:P34948"
FT   BINDING         110
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000250|UniProtKB:P34948"
FT   BINDING         112
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000250|UniProtKB:P34948"
FT   BINDING         137
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000250|UniProtKB:P34948"
FT   BINDING         276
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000250|UniProtKB:P34948"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0007744|PubMed:19413330"
FT   MOD_RES         102
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         108
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   VAR_SEQ         163..224
FT                   /note="KVPEFQFLIGDEAATHLKQTMSHDSQAVASSLQSCFSHLMKSEKKVVVEQLN
FT                   LLVKRISQQA -> T (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_013357"
FT   VARIANT         51
FT                   /note="M -> T (in CDG1B; dbSNP:rs764835081)"
FT                   /evidence="ECO:0000269|PubMed:10980531"
FT                   /id="VAR_022516"
FT   VARIANT         102
FT                   /note="S -> L (in CDG1B; dbSNP:rs104894494)"
FT                   /evidence="ECO:0000269|PubMed:9585601"
FT                   /id="VAR_012338"
FT   VARIANT         129
FT                   /note="Y -> C (in CDG1B; dbSNP:rs887249336)"
FT                   /evidence="ECO:0000269|PubMed:12357336"
FT                   /id="VAR_022517"
FT   VARIANT         131
FT                   /note="D -> N (in CDG1B; dbSNP:rs566620411)"
FT                   /evidence="ECO:0000269|PubMed:10980531"
FT                   /id="VAR_022518"
FT   VARIANT         138
FT                   /note="M -> T (in CDG1B; dbSNP:rs104894495)"
FT                   /evidence="ECO:0000269|PubMed:9585601"
FT                   /id="VAR_012339"
FT   VARIANT         140
FT                   /note="I -> T (in CDG1B; dbSNP:rs773678732)"
FT                   /evidence="ECO:0000269|PubMed:11350186"
FT                   /id="VAR_012345"
FT   VARIANT         152
FT                   /note="R -> Q (in CDG1B; dbSNP:rs766458792)"
FT                   /evidence="ECO:0000269|PubMed:10980531"
FT                   /id="VAR_022519"
FT   VARIANT         219
FT                   /note="R -> Q (in CDG1B; dbSNP:rs104894489)"
FT                   /evidence="ECO:0000269|PubMed:11350186,
FT                   ECO:0000269|PubMed:9525984"
FT                   /id="VAR_012340"
FT   VARIANT         250
FT                   /note="G -> S (in CDG1B; dbSNP:rs748090636)"
FT                   /evidence="ECO:0000269|PubMed:10980531"
FT                   /id="VAR_022520"
FT   VARIANT         255
FT                   /note="Y -> C (in CDG1B)"
FT                   /evidence="ECO:0000269|PubMed:11134235"
FT                   /id="VAR_022521"
FT   VARIANT         295
FT                   /note="R -> H (in CDG1B; dbSNP:rs28928906)"
FT                   /evidence="ECO:0000269|PubMed:12414827"
FT                   /id="VAR_022522"
FT   VARIANT         398
FT                   /note="I -> T (in CDG1B; dbSNP:rs369326210)"
FT                   /evidence="ECO:0000269|PubMed:11134235"
FT                   /id="VAR_022523"
FT   VARIANT         418
FT                   /note="R -> H (in CDG1B; dbSNP:rs863225087)"
FT                   /evidence="ECO:0000269|PubMed:10980531"
FT                   /id="VAR_022524"
SQ   SEQUENCE   423 AA;  46656 MW;  1612DD966B86D3AC CRC64;
     MAAPRVFPLS CAVQQYAWGK MGSNSEVARL LASSDPLAQI AEDKPYAELW MGTHPRGDAK
     ILDNRISQKT LSQWIAENQD SLGSKVKDTF NGNLPFLFKV LSVETPLSIQ AHPNKELAEK
     LHLQAPQHYP DANHKPEMAI ALTPFQGLCG FRPVEEIVTF LKKVPEFQFL IGDEAATHLK
     QTMSHDSQAV ASSLQSCFSH LMKSEKKVVV EQLNLLVKRI SQQAAAGNNM EDIFGELLLQ
     LHQQYPGDIG CFAIYFLNLL TLKPGEAMFL EANVPHAYLK GDCVECMACS DNTVRAGLTP
     KFIDVPTLCE MLSYTPSSSK DRLFLPTRSQ EDPYLSIYDP PVPDFTIMKT EVPGSVTEYK
     VLALDSASIL LMVQGTVIAS TPTTQTPIPL QRGGVLFIGA NESVSLKLTE PKDLLIFRAC
     CLL
//

